Nuvalent at Cantor Global Healthcare Conference 2025
- (Nasdaq: Novl) announced today that its management team will present at the Morgan Stanley Global Healthcare Conference on September 9, 2025, at 11:00 AM ET.
- Nuvalent, Inc.is a clinical-stage biopharmaceutical company dedicated to developing precisely targeted therapies for cancer patients.
- Currently,Nuvalent is advancing a pipeline of investigational candidates targeting ROS1-positive,ALK-positive,and HER2-altered non-small cell lung cancer.
Nuvalent to Present at teh Morgan Stanley Global Healthcare Conference 2025
CAMBRIDGE, Mass. – August 28, 2025 – Nuvalent, Inc. (Nasdaq: Novl) announced today that its management team will present at the Morgan Stanley Global Healthcare Conference on September 9, 2025, at 11:00 AM ET. The presentation will be webcast live and archived for 30 days following the event. the webcast can be accessed at Nuvalent’s website.
About Nuvalent
Nuvalent, Inc.is a clinical-stage biopharmaceutical company dedicated to developing precisely targeted therapies for cancer patients. The company aims to address limitations of existing kinase inhibitor therapies, focusing on overcoming resistance, reducing adverse effects, improving brain penetration, and achieving more durable responses.Nuvalent’s approach leverages deep expertise in chemistry and structure-based drug design.
Currently,Nuvalent is advancing a pipeline of investigational candidates targeting ROS1-positive,ALK-positive,and HER2-altered non-small cell lung cancer. The company also has multiple revelation-stage research programs underway. As of August 28,2025,Nuvalent is traded on the Nasdaq stock exchange under the ticker symbol Novl.
Understanding Kinase Inhibitors and Targeted Therapies
Kinases are enzymes that play a crucial role in cell signaling, and their dysregulation is frequently enough implicated in cancer development. Kinase inhibitors are drugs designed to block the activity of these enzymes, thereby disrupting cancer cell growth and survival. however, cancer cells can develop resistance to these inhibitors through various mechanisms, including mutations in the kinase itself or activation of choice signaling pathways.
Targeted therapies, like those being developed by Nuvalent, aim to overcome these resistance mechanisms by designing drugs that are more selective for the target kinase or that can circumvent the resistance pathways. Structure-based drug design utilizes the three-dimensional structure of the target protein to rationally design molecules that bind with high affinity and specificity.